Volume 121, Issue 12, Pages (December 2014)

Slides:

Advertisements

Similar presentations

Patient Preferences in the Treatment of Neovascular Age-Related Macular Degeneration Sabrina Mueller, MSc, Hansjürgen Agostini, MD, Christoph Ehlken, MD,

Advertisements

Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: The Effect of Latanoprost, Brimonidine, and a Fixed.

Rebamipide (OPC-12759) in the Treatment of Dry Eye: A Randomized, Double-Masked, Multicenter, Placebo-Controlled Phase II Study Shigeru Kinoshita, MD,

Volume 124, Issue 2, Pages (February 2017)

Volume 118, Issue 3, Pages (March 2011)

Volume 121, Issue 12, Pages (December 2014)

Volume 121, Issue 12, Pages (December 2014)

Retinopathy in Persons without Diabetes

American Journal of Ophthalmology

Volume 123, Issue 6, Pages (June 2016)

Volume 118, Issue 2, Pages (February 2011)

Efficacy of Cognitive-Behavioral Therapy for Insomnia Associated With Traumatic Brain Injury: A Single-Case Experimental Design Marie-Christine Ouellet,

Volume 1, Issue 4, Pages (July 2017)

Lifitegrast Ophthalmic Solution 5.0% for Treatment of Dry Eye Disease

Volume 119, Issue 10, Pages (October 2012)

Clinically significant and sustained weight loss is achievable in obese women with polycystic ovary syndrome followed in a regular medical practice Lysanne.

Volume 121, Issue 4, Pages (April 2014)

Visual Impairment and Blindness in Spanish Adults

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo Eli O. Meltzer, MD, Claus Bachert,

Volume 116, Issue 6, Pages (June 2009)

Transscleral Diode Laser Cyclophotocoagulation

Claus Bachert, PhD, Ana R. Sousa, PhD, Valerie J. Lund, MD, Glenis K

Volume 10, Issue 7, Pages (July 2018)

Mindfulness-Oriented Recovery Enhancement Ameliorates the Impact of Pain on Self- Reported Psychological and Physical Function Among Opioid-Using Chronic.

Volume 146, Issue 6, Pages (December 2014)

Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma

The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma Kai-Michael Beeh, MD, Frank Kanniess, MD, Frank Wagner, MD, Cordula.

Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment.

Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance

Once-Daily Gastroretentive Gabapentin for Postherpetic Neuralgia: Integrated Efficacy, Time to Onset of Pain Relief and Safety Analyses of Data From Two.

Inhaler reminders improve adherence with controller treatment in primary care patients with asthma Juliet M. Foster, PhD, Tim Usherwood, BSc, MD, BS,

A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer

J. Alexander Torres, BS, Nathan A. Fischer, BS, Leonard K

Treatment Outcomes of Mitomycin C-Augmented Trabeculectomy, Sub-Tenon Injection versus Soaked Sponges, after 3 Years of Follow-up Hamed Esfandiari, MD,

A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: Results of 2 randomized, double-blind, phase 3 studies Linda.

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

Paul D. Thompson, MD, John Rubino, MD, Matthew J. Janik, MD, Diane E

Long-Term Safety and Efficacy of Morphine Sulfate and Naltrexone Hydrochloride Extended Release Capsules, a Novel Formulation Containing Morphine and.

Mindfulness-Oriented Recovery Enhancement Ameliorates the Impact of Pain on Self- Reported Psychological and Physical Function Among Opioid-Using Chronic.

Erin G. Sieck, MD, Rebecca S. Epstein, MD, Jeffrey B

Functional magnetic stimulation for conditioning of expiratory muscles in patients with spinal cord injury Vernon W. Lin, MD, PhD, Ian N. Hsiao, PhD,

International phase III trial of liprotamase efficacy and safety in pancreatic-insufficient cystic fibrosis patients Drucy Borowitz, Christopher Stevens,

Efficacy of Cognitive-Behavioral Therapy for Insomnia Associated With Traumatic Brain Injury: A Single-Case Experimental Design Marie-Christine Ouellet,

Palliative Radiation Before Hospice: The Long and the Short of It

Volume 53, Issue 6, Pages (June 2008)

Supported Treadmill Ambulation for Amyotrophic Lateral Sclerosis: A Pilot Study Mohammed Sanjak, PhD, PT, Elena Bravver, MD, William L. Bockenek, MD,

Improving the Feasibility of Glaucoma Clinical Trials Using Trend-Based Visual Field Progression End Points Zhichao Wu, BAppSc(Optom), PhD, David P.

Correlation between Intraocular Pressure and Angle Configuration Measured by OCT Benjamin Y. Xu, MD, PhD, Bruce Burkemper, PhD, Juan Pablo Lewinger, PhD,

Botulinum Toxin Type A Injections for Treating Neurogenic Detrusor Overactivity Combined With Low-Compliance Bladder in Patients With Spinal Cord Lesions

Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial Hendrik.

Factors Affecting Adherence to Topical Glaucoma Therapy

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo Eli O. Meltzer, MD, Claus Bachert,

Ophthalmology Glaucoma

Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup:

Micropulse Transscleral Cyclophotocoagulation

Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial Sonja Ständer, MD, Paul Kwon, MD,

Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3.

Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down Eric D. Bateman, MD, Loretta Jacques, PhD,

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Tofacitinib therapy for children with severe alopecia areata

Ophthalmology Glaucoma

Blake R. Zelickson, MD, PhD, Leonard H. Goldberg, MD, Marc K

Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a.

Acute Stress Increases Intraocular Pressure in Nonhuman Primates

Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle.

Volume 82, Issue 11, Pages (December 2012)

Alan Menter, MD, Stephen K

Ophthalmology Glaucoma

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistent erythema of rosacea through 52 weeks of treatment Michael.

Presentation transcript:

Volume 121, Issue 12, Pages 2348-2355 (December 2014) Twice-Daily Brinzolamide/Brimonidine Fixed Combination versus Brinzolamide or Brimonidine in Open-Angle Glaucoma or Ocular Hypertension Tin Aung, FRCS, PhD, Guna Laganovska, MD, Tania Josefina Hernandez Paredes, MD, James D. Branch, MD, Alexis Tsorbatzoglou, MD, PhD, Ivan Goldberg, AM, FRANZCO Ophthalmology Volume 121, Issue 12, Pages 2348-2355 (December 2014) DOI: 10.1016/j.ophtha.2014.06.022 Copyright © 2014 American Academy of Ophthalmology Terms and Conditions

Figure 1 Patient disposition. BBFC = brinzolamide 1%/brimonidine 0.2% fixed combination; IOP = intraocular pressure; ITT = intent-to-treat. Ophthalmology 2014 121, 2348-2355DOI: (10.1016/j.ophtha.2014.06.022) Copyright © 2014 American Academy of Ophthalmology Terms and Conditions

Figure 2 The least squares (LS) mean changes in diurnal intraocular pressure (IOP) (i.e., average of IOP at 9 am, 11 am, and 4 pm time points) from baseline throughout the study (intent-to-treat [ITT] population). Error bars represent standard errors. P values for the primary efficacy end point (between-group differences at month 3) and descriptive P values for supportive efficacy end points (i.e., between-group differences at week 2 and month 6) are provided. BBFC = brinzolamide 1%/brimonidine 0.2% fixed combination. *P ≤ 0.0001. †Primary end point. Ophthalmology 2014 121, 2348-2355DOI: (10.1016/j.ophtha.2014.06.022) Copyright © 2014 American Academy of Ophthalmology Terms and Conditions

Figure 3 Mean change in intraocular pressure (IOP) from baseline at all time points at week 2, month 3, and month 6 visits (intent-to-treat [ITT] population). Error bars represent standard errors. BBFC = brinzolamide 1%/brimonidine 0.2% fixed combination. Ophthalmology 2014 121, 2348-2355DOI: (10.1016/j.ophtha.2014.06.022) Copyright © 2014 American Academy of Ophthalmology Terms and Conditions

Figure 4 Percentage of patients who achieved intraocular pressure (IOP) <18 mmHg (intent-to-treat [ITT] population). BBFC = brinzolamide 1%/brimonidine 0.2% fixed combination. Ophthalmology 2014 121, 2348-2355DOI: (10.1016/j.ophtha.2014.06.022) Copyright © 2014 American Academy of Ophthalmology Terms and Conditions